Drug Type Small molecule drug |
Synonyms Elaspol, Sivelestat, Sivelestat Sodium(USAN) + [11] |
Target |
Mechanism ELA2 inhibitors(Leukocyte elastase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date JP (11 Apr 2002), |
RegulationOrphan Drug (US) |
Molecular FormulaC20H30N2NaO11S |
InChIKeyZTSWBOROHLPTLV-UHFFFAOYSA-N |
CAS Registry201677-61-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Sivelestat Sodium Hydrate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Acute Lung Injury | JP | 11 Apr 2002 | |
Acute Lung Injury | JP | 11 Apr 2002 | |
Systemic Inflammatory Response Syndrome | JP | 11 Apr 2002 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Heart Diseases | Phase 3 | - | 18 Feb 2024 | |
Respiratory Distress Syndrome, Acute | Phase 3 | - | 18 Feb 2024 | |
Pulmonary Fibrosis | Phase 3 | JP | - | |
Pneumonia | Phase 2 | JP | 01 Dec 2006 | |
Respiratory Distress Syndrome, Adult | Phase 2 | US | 01 Aug 2001 | |
Respiratory Distress Syndrome, Adult | Phase 2 | AU | 01 Aug 2001 | |
Respiratory Distress Syndrome, Adult | Phase 2 | BE | 01 Aug 2001 | |
Respiratory Distress Syndrome, Adult | Phase 2 | CA | 01 Aug 2001 | |
Respiratory Distress Syndrome, Adult | Phase 2 | NZ | 01 Aug 2001 | |
Respiratory Distress Syndrome, Adult | Phase 2 | ES | 01 Aug 2001 |
Not Applicable | 665 | iqcfagabag(ycvzbgewlr) = xutzmgrecx mlqsnzzqga (sprbkkgfjy ) View more | - | 01 Jan 2023 | |||
(Control) | iqcfagabag(ycvzbgewlr) = kshpvpuack mlqsnzzqga (sprbkkgfjy ) View more | ||||||
Not Applicable | - | 120 | Group A | tbkevduhbi(opedvhwufg) = vbtskgkiol miilhndpjz (wlzqkxuwab ) | Positive | 01 Oct 2008 | |
(Group B) | tbkevduhbi(opedvhwufg) = igyleefooc miilhndpjz (wlzqkxuwab ) View more |